No More Eye Injections for Wet Macular Degeneration?

Genetech has formulated Lucentis’ active ingredient into a refillable eye implant that delivers the medication continuously into the eyes of wet macular degeneration patients. Known as the Port Delivery System, the implantable drug has shown promising results in the second phase of clinical studies. The Port Delivery System is slightly bigger than a grain of […]

Eat an orange a day to keep the AMD away

Oranges are the latest fruit to win accolades for their potential health benefits. The latest study was published in the American Journal of Clinical Nutrition. Researchers at the Westmead Institute for Medical Research were examining the effect flavonoids had on age-related macular degeneration (AMD). More than 2,000 Australian adults aged 50 and over were interviewed […]

Vision loss reversed with new stem cell therapy

A Phase 1 Clinical study of an experimental stem cell treatment for the web form of macular degeneration has resulted in two people having their vision loss reversed and their vision improving to being able to read with reading glasses. The study was published in Nature Biotechnology. Doctors used a surgical tool specifically designed for […]

Study compares Lucentis regimens for wet AMD

The treat-and-extend (TE) protocol of Lucentis (ranibizumab) is just as effective as a monthly regimen of ranibizumab when looking at increasing visual acuity in patients with neovascular age-related macular degeneration (AMD). The 12-month study was conducted in Portugal and led by Rufino Silvia, MD, PhD and involved 650 wet AMD patients aged 50 and older. […]

BREAKTHROUGH – Blood test for Macular Degeneration?

Researchers at Massachusetts Eye and Ear have found that a particular set of metabolites in the blood are good markers for diagnosing AMD as well as indicating the severity of Macular Degeneration Metabolites, or breakdown products, are a result of both genes and environment. The “metabolome” — the set of metabolites present in an individual — […]

Discontinuing macular degeneration injections results in vision loss

A retrospective, observational study examined the data from 35 patients who had received anti-VEGF injections of the eye for treatment of the wet form of macular degeneration but then stopped treatment despite continued symptoms. Researchers found a notable deterioration in visual acuity over two years. Researchers looked at the best-corrected visual acuity (BCVA) at the […]

Eye injections increase glaucoma risk

Patients who receive seven or more Intravitreous eye injections of bevacizumab (Avastin) each year are at a higher risk of eventually needing glaucoma surgery according to study results recently published in the JAMA Ophthalmology medical journal. Intravitreous injections are the standard therapy for patients suffering from the wet form of macular degeneration. Researchers examined data […]

App allows users to ‘see’ retinal disease

A new virtual and augmented reality app called “In My Eyes” allows users to experience what it is like to have different kinds of retinal disease. Regeneron Pharmaceuticals teamed with Intouch Solutions to create the app. Available for free download in the iTunes and Google app stores, the app can be used with or without […]

Testing of drug underway for patients with wet macular degeneration

A new drug that is currently being tested on mice and rabbits requires fewer injections than the current standard intravitreal therapy for age-related macular degeneration (AMD). Researchers are hopeful that injections in humans would have a longer-lasting effect: several months between injections instead of every four to six weeks. The new drug lasted two months […]

Macular Degeneration may Start in Gut

Researchers at the University of Montreal examined how bacterial flora in the intestinal tract may influence the risk of developing the wet (neovascular) form of macular degeneration. Wet AMD is characterize by the formation and leakage of new and weak blood vessels in the eye. Obesity is one of the five most common factors related […]